Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts

Abstract

Background: Oral moist snuff (snus) is discussed as a safer alternative to smoking, and its use is increasing. Based on its documented effect on blood pressure, we hypothesized that use of snus increases the risk of heart failure.

Design: Two independent Swedish prospective cohorts; the Uppsala Longitudinal Study of Adult Men (ULSAM), a community-based sample of 1076 elderly men, and the Construction Workers Cohort (CWC), a sample of 118,425 never-smoking male construction workers.

Methods: Cox proportional hazards models were used to investigate possible associations of snus use with risk of a first hospitalization for heart failure.

Results: In ULSAM, 95 men were hospitalized for heart failure, during a median follow up of 8.9 years. In a model adjusted for established risk factors including past and present smoking exposure, current snus use was associated with a higher risk of heart failure [hazard ratio (HR) 2.08, 95% confidence interval (CI) 1.03⊟4.22] relative to non-use. Snus use was particularly associated with risk of non-ischaemic heart failure (HR 2.55, 95% CI 1.12⊟5.82). In CWC, 545 men were hospitalized for heart failure, during a median follow up of 18 years. In multivariable-adjusted models, current snus use was moderately associated with a higher risk of heart failure (HR 1.28, 95% CI 1.00⊟1.64) and non-ischaemic heart failure (HR 1.28, 95% CI 0.97⊟1.68) relative to never tobacco use.

Conclusion: Data from two independent cohorts suggest that use of snus may be associated with a higher risk of heart failure.

Keywords

Epidemiology heart failure risk factors smokeless tobacco snus

Get full access to this article

View all access options for this article.

References

SCB/ULF (Statistics Sweden). 2007.

AC Nielsen and Swedish Match. Market for snus and snuff http://www.swedishmatch.com/en/Our-business/Snuff-and-snus/Market/ (consulted March 2011).

Schmidt

. A change in the air: smoking bans gain momentum worldwide. World Hosp Health Serv 2007; 43: 37–39.

Boffetta

Straif

. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009; 339: b3060–b3060.

Hansson

Pedersen

Galanti

Andersson

Ahlbom

Hallqvist

. Use of snus and risk for cardiovascular disease: results from the Swedish Twin Registry. J Intern Med 2009; 265: 717–724.

Wolk

Shamsuzzaman

Svatikova

Huyber

Huck

Narkiewicz

. Hemodynamic and autonomic effects of smokeless tobacco in healthy young men. J Am Coll Cardiol 2005; 45: 910–914.

Granberry

Smith

3 rd, ES

Troillett

Edit

. Forearm endothelial response in smokeless tobacco users compared with cigarette smokers and nonusers of tobacco. Pharmacotherapy 2003; 23: 974–978.

Rohani

Agewall

. Oral snuff impairs endothelial function in healthy snuff users. J Intern Med 2004; 255: 379–383.

Bolinder

de Faire

. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. Am J Hypertens 1998; 11: 1153–1163.

10.

Hergens

Lambe

Pershagen

. Risk of hypertension amongst Swedish male snuff users: a prospective study. J Intern Med 2008; 264: 187–194.

11.

Levy

Larson

Vasan

Kannel

. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562.

12.

Berry

Murdoch

McMurray

JJV

. Economics of chronic heart failure. Eur J Heart Fail 2001; 3: 283–291.

13.

Ingelsson

Bjorklund-Bodegard

Lind

Arnlov

Sundstrom

. Diurnal Blood Pressure Pattern and Risk of Congestive Heart Failure. JAMA 2006; 295: 2859–2866.

14.

Hergens

Alfredsson

Bolinder

Lambe

Pershagen

. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007; 262: 351–359. Erratum in J Intern Med 2007; 262(5): 590.).

15.

Zendehdel

Nyren

Luo

Dickman

Boffetta

Englund

. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008; 122: 1095–1099.

16.

Ingelsson

Arnlov

Sundstrom

Lind

. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 2005; 7: 787–791.

17.

Guidelines for the diagnosis of heart failure. The task force on heart failure of the European Society of Cardiology. Eur Heart J 1995; 16: 741–751.

18.

Teo

Ounpuu

Hawken

Pandey

Valentin

Hunt

. INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368: 647–658.

19.

Hergens

Ahlbom

Andersson

Pershagen

. Swedish moist snuff and myocardial infarction among men. Epidemiology 2005; 16: 12–16.

20.

Janzon

Hedblad

. Swedish snuff and incidence of cardiovascular disease. A population-based cohort study. BMC Cardiovasc Disord 2009; 9: 21–21.

21.

Huhtasaari

Asplund

Lundberg

Stegmayr

Wester

. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ 1992; 305: 1252–1256.

22.

Huhtasaari

Lundberg

Eliasson

Janlert

Asplund

. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. JACC 1999; 34: 1784–1790.

23.

Haglund

Eliasson

Stenbeck

Rosen

. Is moist snuff use associated with excess risk of IHD or stroke? A longitudinal follow-up of snuff users in Sweden. Scand J Public Health 2007; 35: 618–622.

24.

Wennberg

Eliasson

Hallmans

Johansson

Boman

Jansson

. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. J Intern Med 2007; 262: 360–367.

25.

Johansson

Sundquist

Qvist

Sundquist

. Smokeless tobacco and coronary heart disease: a 12-year follow-up study. Eur J Cardiovasc Prev Rehabil 2005; 12: 387–392.

26.

Laks

Morady

Swan

HJC

. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 1973; 64: 75–78.

27.

Kannel

Levy

Cupples

. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987; 10: 135–140.

28.

Lunell

. Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: A crossover study. Nicotine Tob Res 2005; 7: 397–403.

29.

Luo

Zendehdel

Adami

Boffetta

. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007; 369: 2015–2020.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB